Skip to main content
SpringerLink
Log in

How Should we Treat Tophaceous Gout in Patients with Allopurinol Hypersensitivity?

  • Chapter
Purine and Pyrimidine Metabolism in Man IX

Part of the book series: Advances in Experimental Medicine and Biology ((AEMB,volume 431))

Summary

We studied purine metabolism in gouty patients from three categories: primary gout, familial juvenile hyperuricaemic nephropathy (FJHN) and partial HPRT deficiency.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Fox IH, Sinclair DS. The Pharmacology of the hypouricemic effect of benzbromarone. Adv Exp Med Biol 1977; 76B: 328–323.

    Article  PubMed  CAS  Google Scholar 

  2. Zürcher R M, Bock H A, Thiel G. Excellent efficacy of benzbromarone in cyclosporine-A-treated renal transplant patients:a prospective study. Nephrol Dial Transplant 1994; 9: 548–551.

    PubMed  Google Scholar 

  3. Cameron JS, Moro F, McBride M B, Simmonds H A. Inherited disorders of purine metabolism and transport. Chapter 16.5.3 in Oxford Textbook of Clinical Nephrology. 1997 pp 13–26.

    Google Scholar 

  4. Allopurinol in treatment of gout. Scott J T, Hall A P, Grahame R Brit Med JI 1966; 2: 321–327.

    Article  CAS  Google Scholar 

  5. Mclnnes et al. Acute adverse reactions to allopurinol in hospitalised patients. Ann Rheum Dis 1981; 40: 245–249.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Rheumatology, UK

    R. Grahame

  2. Purine Research Laboratory UMDS, Guy’s Hospital, UK

    H. A. Simmonds & M. B. McBride

  3. Department of Nephrology, Royal London Hospital, London, UK

    F. P. Marsh

Authors
  1. R. Grahame
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H. A. Simmonds
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. B. McBride
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. F. P. Marsh
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Emperor Franz Joseph Hospital, Vienna, Austria

    Andrea Griesmacher  & Mathias M. Müller  & 

  2. University of Vienna, Vienna, Austria

    Peter Chiba

Rights and permissions

Reprints and permissions

Copyright information

© 1998 Springer Science+Business Media New York

About this chapter

Cite this chapter

Grahame, R., Simmonds, H.A., McBride, M.B., Marsh, F.P. (1998). How Should we Treat Tophaceous Gout in Patients with Allopurinol Hypersensitivity?. In: Griesmacher, A., Müller, M.M., Chiba, P. (eds) Purine and Pyrimidine Metabolism in Man IX. Advances in Experimental Medicine and Biology, vol 431. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-5381-6_4

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-5381-6_4

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-7456-5

  • Online ISBN: 978-1-4615-5381-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation